New drug aims to let Sun-Sensitive patients enjoy daylight
NCT ID NCT04402489
Summary
This study tested whether an investigational drug called MT-7117 could help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). These conditions cause severe burning, tingling, or stinging pain soon after sunlight exposure. The trial involved 184 participants aged 12-75 and measured if the drug could safely increase the time they could spend in the sun before symptoms began.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
Brescia, 1 25123, Italy
-
Charite - Universitaetsmedizin Berlin
Berlin, 10117, Germany
-
Evelina London Children's Hospital - Guy's & St Thomas' NHS Foundation Trust
London, SE1 7EH, United Kingdom
-
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
Milan, 20122, Italy
-
Haukeland University Hospital
Bergen, Norway
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
I.F.O Hospital Centro Porfirie e Malattie Rare
Rome, 144 Rome RM, Italy
-
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York, 10029, United States
-
Investigator site
Sayama, Osaka, Japan
-
Kansas City Research Institute
Kansas City, Missouri, 64131, United States
-
Karolinska University Hospital
Stockholm, 171 64, Sweden
-
Kobe University Hospital
Kobe, Hyōgo, Japan
-
Marvel Clinical Research, LLC
Huntington Beach, California, 92647, United States
-
MetroBoston Clinical Partners, LLC
Brighton, Massachusetts, 02135, United States
-
Osaka Medical College Hospital
Takatsuki, Osaka, Japan
-
Remington-Davis Clinical Research
Columbus, Ohio, 43215, United States
-
Royal Melbourne Hospital (RMH)
Melbourne, Victoria, 3050, Australia
-
Sophia Dermatology Clinic
Kanazawa, Ishikawa-ken, 921-8035, Japan
-
The University of Texas Medical Branch (UTMB)
Galveston, Texas, 77555, United States
-
The Wesley Hospital
Brisbane, Queensland, 4066, Australia
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Tokyo Saiseikai Central Hospital
Minato-ku, Tokyo, Japan
-
Toyama University Hospital
Sugitani, Toyama, 930-0194, Japan
-
U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena
Modena, 41125, Italy
-
University Of Miami School Of Medicine, Center For Liver Diseases
Miami, Florida, 33136, United States
-
University of Alberta
Edmonton, Alberta, AB T6G 2R3, Canada
-
University of Manchester
Salford, Manchester, M13 9PL, United Kingdom
-
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington, 19023, United States
-
Wake Forest University Baptist Health
Winston-Salem, North Carolina, 27109, United States
-
Westfaelische Wilhelms-Universitaet Muenster
Münster, Northrhein Westalien, 48149, Germany
Conditions
Explore the condition pages connected to this study.